Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2017-03-29 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
2016年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2016 by 西藏易明西雅医药科技股份有限公司. It contains detailed descriptions of the company's internal control evaluation, including principles, scope, defect classification standards, and conclusions about the effectiveness of internal controls over financial reporting and non-financial reporting. The document is comprehensive and contains substantive content related to internal control evaluation rather than just an announcement or summary. It does not fit the definitions of Annual Report (10-K), Earnings Release, or other financial reports but aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and audit-related information. Therefore, the appropriate classification is AR (Audit Report / Information). The document length (6376 characters) supports it being a full report rather than a brief announcement. FY 2016
2017-03-29 Chinese
第一届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the first Supervisory Board of the company, including approvals of various reports such as the 2016 Supervisory Board Work Report, audited financial statements, annual report, profit distribution plan, and other related matters. It references that these reports are published on external websites for investors to review, indicating that the document itself is not the full annual report but a meeting resolution announcement. The document is under 5,000 characters and primarily serves to disclose the meeting decisions and approvals, not the full financial or management report. Therefore, it fits best as a Regulatory Filing (RNS) rather than the Annual Report (10-K) or Management Report (MDA).
2017-03-29 Chinese
独立董事关于第一届董事会第十七次会议有关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the company's first board of directors' 17th meeting. It covers topics such as the 2016 profit distribution plan, the use and storage of raised funds, related party transactions, reappointment of the audit firm, internal control self-assessment, lease agreements with related parties, use of raised funds for loans to subsidiaries, and accounting policy changes. The document references specific reports like the 2016 audit report and internal control self-assessment report but does not itself contain full financial statements or detailed financial data. It is a formal opinion letter related to board meeting matters and governance, rather than a full annual report or audit report. The document length is 3253 characters, which is relatively short and consistent with an opinion or governance-related document. Therefore, the best fitting category is Board/Management Information (MANG), as it relates to board meeting opinions and governance matters.
2017-03-29 Chinese
关于子公司向关联方周战先生续租房产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a related party transaction where a subsidiary of the company is renewing a lease agreement with a related party who is a shareholder, director, and vice general manager. It details the transaction terms, pricing policy, approvals by the board and independent directors, and includes opinions from the sponsor institution. The document is a formal disclosure of a related party transaction, not a financial report, earnings release, or management discussion. It does not contain financial statements or results but focuses on governance and compliance with related party transaction rules. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements and compliance disclosures that do not fit other specific categories.
2017-03-29 Chinese
关于使用募集资金向子公司提供借款实施募投项目的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of raised funds (募集资金) to provide a loan to its subsidiary for a specific investment project. It details the approval by the board, the amount of funds raised, the loan agreement, and opinions from independent directors, the supervisory board, and the sponsoring institution. The document is relatively short (3690 characters) and primarily serves as a formal disclosure of a financing activity related to capital raised from a public offering. It does not contain comprehensive financial statements or detailed financial performance data. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2017-03-29 Chinese
上市公司内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an internal control rules implementation self-inspection checklist for a listed company, 西藏易明西雅医药科技股份有限公司. It details internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a detailed internal control compliance checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings such as annual or interim reports. It is not a certification or a brief announcement but a substantive internal control report. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and internal control disclosure that does not fit other specific categories like Annual Report or Audit Report. The document length is 4118 characters, which is substantive but not a full financial report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2017-03-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.